Obstructive Coronary Artery Disease: A Review of the Medicinal Chemistry of Atherosclerosis and Gold-Standard Treatments with Metoprolol and Atorvastatin
DOI:
https://doi.org/10.58445/rars.3118Keywords:
Coronary Artery Disease (CAD), Atherosclerosis, Obstructive Coronary Artery DiseaseAbstract
This review focuses on the medicinal chemistry aspects of Coronary Artery Disease (CAD). As an exercise for the broad scope of medicinal chemistry, this review will highlight the design, synthesis, pharmacodynamics, and pharmacokinetics of two gold standard medications for Obstructive Coronary Artery Disease (OCAD). This review begins with an introduction that provides an overview of coronary artery disease, including its scope and history. Supplemented with statistics, the introduction will then lead into the pathology behind atherosclerosis, most notably the cell processes that lead to the disease. After that, the body of the paper extensively discusses two gold standard treatments for coronary artery disease, while also mentioning the rationale behind these two treatments. There will be accompanying figures in the body of the paragraph, or when statistics are relevant.
References
(1) Libby, P.; Theroux, P. Pathophysiology of Coronary Artery Disease. Circulation 2005, 111 (25), 3481–3488. https://doi.org/10.1161/CIRCULATIONAHA.105.537878.
(2) Bentzon, J. F.; Otsuka, F.; Virmani, R.; Falk, E. Mechanisms of Plaque Formation and Rupture. Circ. Res. 2014, 114 (12), 1852–1866. https://doi.org/10.1161/CIRCRESAHA.114.302721.
(3) Kyker, K. A.; Limacher, M. C. Gender Differences in the Presentation and Symptoms of Coronary Artery Disease. Curr. Womens Health Rep. 2002, 2 (2), 115–119.
(4) Brown, J. C.; Gerhardt, T. E.; Kwon, E. Risk Factors for Coronary Artery Disease. In StatPearls; StatPearls Publishing: Treasure Island (FL), 2025.
(5) Madhavan, M. V.; Gersh, B. J.; Alexander, K. P.; Granger, C. B.; Stone, G. W. Coronary Artery Disease in Patients ≥80 Years of Age. J. Am. Coll. Cardiol. 2018, 71 (18), 2015–2040. https://doi.org/10.1016/j.jacc.2017.12.068.
(6) Vähätalo, J.; Holmström, L.; Pakanen, L.; Kaikkonen, K.; Perkiömäki, J.; Huikuri, H.; Junttila, J. Coronary Artery Disease as the Cause of Sudden Cardiac Death Among Victims < 50 Years of Age. Am. J. Cardiol. 2021, 147, 33–38. https://doi.org/10.1016/j.amjcard.2021.02.012.
(7) Pizzi, C.; Xhyheri, B.; Costa, G. M.; Faustino, M.; Flacco, M. E.; Gualano, M. R.; Fragassi, G.; Grigioni, F.; Manzoli, L. Nonobstructive Versus Obstructive Coronary Artery Disease in Acute Coronary Syndrome: A Meta‐Analysis. J. Am. Heart Assoc. 2016, 5 (12), e004185. https://doi.org/10.1161/JAHA.116.004185.
(8) Dalen, J. E.; Alpert, J. S.; Goldberg, R. J.; Weinstein, R. S. The Epidemic of the 20th Century: Coronary Heart Disease. Am. J. Med. 2014, 127 (9), 807–812. https://doi.org/10.1016/j.amjmed.2014.04.015.
(9) More than half of U.S. adults don’t know heart disease is leading cause of death, despite 100-year reign. American Heart Association. https://newsroom.heart.org/news/more-than-half-of-u-s-adults-dont-know-heart-disease-is-leading-cause-of-death-despite-100-year-reign (accessed 2025-08-15).
(10) Young, S. G. Recent Progress in Understanding Apolipoprotein B. Circulation 1990, 82 (5), 1574–1594. https://doi.org/10.1161/01.CIR.82.5.1574.
(11) Welty, F. K.; Lichtenstein, A. H.; Barrett, P. H. R.; Dolnikowski, G. G.; Schaefer, E. J. Human Apolipoprotein (Apo) B-48 and ApoB-100 Kinetics With Stable Isotopes. Arterioscler. Thromb. Vasc. Biol. 1999, 19 (12), 2966–2974. https://doi.org/10.1161/01.ATV.19.12.2966.
(12) Atherosclerosis Topic Review. https://www.healio.com/cardiology/learn-the-heart/cardiology-review/topic-reviews/atherosclerosis (accessed 2025-08-15).
(13) Liu, X.; Wu, J.; Tian, R.; Su, S.; Deng, S.; Meng, X. Targeting Foam Cell Formation and Macrophage Polarization in Atherosclerosis: The Therapeutic Potential of Rhubarb. Biomed. Pharmacother. 2020, 129, 110433. https://doi.org/10.1016/j.biopha.2020.110433.
(14) Sever, P. S.; Dahlöf, B.; Poulter, N. R.; Wedel, H.; Beevers, G.; Caulfield, M.; Collins, R.; Kjeldsen, S. E.; Kristinsson, A.; McInnes, G. T.; Mehlsen, J.; Nieminen, M.; O’Brien, E.; Ostergren, J. Prevention of Coronary and Stroke Events with Atorvastatin in Hypertensive Patients Who Have Average or Lower-than-Average Cholesterol Concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): A Multicentre Randomised Controlled Trial. Drugs 2004, 64 (Supplement 2), 43–60. https://doi.org/10.2165/00003495-200464002-00005.
(15) Hjalmarson, Å.; Goldstein, S.; Fagerberg, B.; Wedel, H.; Waagstein, F.; Kjekshus, J.; Wikstrand, J.; El Allaf, D.; Vítovec, J.; Aldershvile, J.; Halinen, M.; Dietz, R.; Neuhaus, K.-L.; Jánosi, A.; Thorgeirsson, G.; Dunselman, P. H. J. M.; Gullestad, L.; Kuch, J.; Herlitz, J.; Rickenbacher, P.; Ball, S.; Gottlieb, S.; Deedwania, P.; For The Merit-Hf Study Group. Effects of Controlled-Release Metoprolol on Total Mortality, Hospitalizations, and Well-Being in Patients With Heart Failure: The Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). JAMA 2000, 283 (10), 1295. https://doi.org/10.1001/jama.283.10.1295.
(16) Nitrovasodilator - an overview | ScienceDirect Topics. https://www.sciencedirect.com/topics/medicine-and-dentistry/nitrovasodilator (accessed 2025-08-15).
(17) Lee, P. M.; Gerriets, V. Nitrates. In StatPearls; StatPearls Publishing: Treasure Island (FL), 2025.
(18) Divakaran, S.; Loscalzo, J. The Role of Nitroglycerin and Other Nitrogen Oxides in Cardiovascular Therapeutics. J. Am. Coll. Cardiol. 2017, 70 (19), 2393–2410. https://doi.org/10.1016/j.jacc.2017.09.1064.
(19) Baker, J. G.; Hill, S. J.; Summers, R. J. Evolution of β-Blockers: From Anti-Anginal Drugs to Ligand-Directed Signalling. Trends Pharmacol. Sci. 2011, 32 (4), 227–234. https://doi.org/10.1016/j.tips.2011.02.010.
(20) Tucker, W. D.; Sankar, P.; Theetha Kariyanna, P. Selective Beta-1 Blockers. In StatPearls; StatPearls Publishing: Treasure Island (FL), 2025.
(21) Farzam, K.; Jan, A. Beta Blockers. In StatPearls; StatPearls Publishing: Treasure Island (FL), 2025.
(22) Braun, M. M.; Stevens, W. A.; Barstow, C. H. Stable Coronary Artery Disease: Treatment. Am. Fam. Physician 2018, 97 (6), 376–384.
(23) Endo, A. A Historical Perspective on the Discovery of Statins. Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. 2010, 86 (5), 484–493. https://doi.org/10.2183/pjab.86.484.
(24) Patel, K. K.; Sehgal, V. S.; Kashfi, K. Molecular Targets of Statins and Their Potential Side Effects: Not All the Glitter Is Gold. Eur. J. Pharmacol. 2022, 922, 174906. https://doi.org/10.1016/j.ejphar.2022.174906.
(25) Sizar, O.; Khare, S.; Patel, P.; Talati, R. Statin Medications. In StatPearls; StatPearls Publishing: Treasure Island (FL), 2025.
(26) Morris, J.; Awosika, A. O.; Dunham, A. Metoprolol. In StatPearls; StatPearls Publishing: Treasure Island (FL), 2025.
(27) Wikstrand, J.; Warnold, I.; Tuomilehto, J.; Olsson, G.; Barber, H. J.; Eliasson, K.; Elmfeldt, D.; Jastrup, B.; Karatzas, N. B.; Leer, J. Metoprolol versus Thiazide Diuretics in Hypertension. Morbidity Results from the MAPHY Study. Hypertension 1991, 17 (4), 579–588. https://doi.org/10.1161/01.HYP.17.4.579.
(28) Gibson, C. M.; Pride, Y. B.; Hochberg, C. P.; Sloan, S.; Sabatine, M. S.; Cannon, C. P. Effect of Intensive Statin Therapy on Clinical Outcomes Among Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndrome. J. Am. Coll. Cardiol. 2009, 54 (24), 2290–2295. https://doi.org/10.1016/j.jacc.2009.09.010.
(29) 米春来; 陈凯; 魏淑冬; 边玢; 姚文静; 龙永鹏. Synthesis Method of Metoprolol Succinate. CN103102281A, May 15, 2013. https://patents.google.com/patent/CN103102281A/en (accessed 2025-08-15).
(30) Alhayek, S.; Preuss, C. V. Beta 1 Receptors. In StatPearls; StatPearls Publishing: Treasure Island (FL), 2025.
(31) Berthiaume, J. M.; Kirk, J. A.; Ranek, M. J.; Lyon, R. C.; Sheikh, F.; Jensen, B. C.; Hoit, B. D.; Butany, J.; Tolend, M.; Rao, V.; Willis, M. S. Pathophysiology of Heart Failure and an Overview of Therapies. In Cardiovascular Pathology; Elsevier, 2016; pp 271–339. https://doi.org/10.1016/B978-0-12-420219-1.00008-2.
(32) Sweeney, H. L.; Hammers, D. W. Muscle Contraction. Cold Spring Harb. Perspect. Biol. 2018, 10 (2), a023200. https://doi.org/10.1101/cshperspect.a023200.
(33) Zamir, A.; Hussain, I.; Ur Rehman, A.; Ashraf, W.; Imran, I.; Saeed, H.; Majeed, A.; Alqahtani, F.; Rasool, M. F. Clinical Pharmacokinetics of Metoprolol: A Systematic Review. Clin. Pharmacokinet. 2022, 61 (8), 1095–1114. https://doi.org/10.1007/s40262-022-01145-y.
(34) Whirl‐Carrillo, M.; Huddart, R.; Gong, L.; Sangkuhl, K.; Thorn, C. F.; Whaley, R.; Klein, T. E. An Evidence‐Based Framework for Evaluating Pharmacogenomics Knowledge for Personalized Medicine. Clin. Pharmacol. Ther. 2021, 110 (3), 563–572. https://doi.org/10.1002/cpt.2350.
(35) Whirl-Carrillo, M.; McDonagh, E. M.; Hebert, J. M.; Gong, L.; Sangkuhl, K.; Thorn, C. F.; Altman, R. B.; Klein, T. E. Pharmacogenomics Knowledge for Personalized Medicine. Clin. Pharmacol. Ther. 2012, 92 (4), 414–417. https://doi.org/10.1038/clpt.2012.96.
(36) Baker, J. G. The Selectivity of β ‐adrenoceptor Antagonists at the Human β 1, β 2 and β 3 Adrenoceptors. Br. J. Pharmacol. 2005, 144 (3), 317–322. https://doi.org/10.1038/sj.bjp.0706048.
(37) Lee, H.-W.; Kim, Y.-M.; Yoo, C.-L.; Kang, S.-K.; Ahn, S.-K. An Efficient Method for the Large-Scale Synthesis of Atorvastatin Calcium. Biomol. Ther. 2008, 16 (1), 28–33. https://doi.org/10.4062/biomolther.2008.16.1.028.
(38) Burnett, J. R.; Wilcox, L. J.; Telford, D. E.; Kleinstiver, S. J.; Barrett, P. H. R.; Newton, R. S.; Huff, M. W. Inhibition of HMG-CoA Reductase by Atorvastatin Decreases Both VLDL and LDL Apolipoprotein B Production in Miniature Pigs. Arterioscler. Thromb. Vasc. Biol. 1997, 17 (11), 2589–2600. https://doi.org/10.1161/01.ATV.17.11.2589.
(39) Oesterle, A.; Laufs, U.; Liao, J. K. Pleiotropic Effects of Statins on the Cardiovascular System. Circ. Res. 2017, 120 (1), 229–243. https://doi.org/10.1161/circresaha.116.308537.
(40) McIver, L. A.; Siddique, M. S. Atorvastatin. In StatPearls; StatPearls Publishing: Treasure Island (FL), 2025.
(41) Tricarico, P. M.; Crovella, S.; Celsi, F. Mevalonate Pathway Blockade, Mitochondrial Dysfunction and Autophagy: A Possible Link. Int. J. Mol. Sci. 2015, 16 (7), 16067–16084. https://doi.org/10.3390/ijms160716067.
(42) Buhaescu, I.; Izzedine, H. Mevalonate Pathway: A Review of Clinical and Therapeutical Implications. Clin. Biochem. 2007, 40 (9–10), 575–584. https://doi.org/10.1016/j.clinbiochem.2007.03.016.
(43) Griffin, S.; Preta, G.; Sheldon, I. M. Inhibiting Mevalonate Pathway Enzymes Increases Stromal Cell Resilience to a Cholesterol-Dependent Cytolysin. Sci. Rep. 2017, 7 (1), 17050. https://doi.org/10.1038/s41598-017-17138-y.
(44) Peng, S.; Xu, L.-W.; Che, X.-Y.; Xiao, Q.-Q.; Pu, J.; Shao, Q.; He, B. Atorvastatin Inhibits Inflammatory Response, Attenuates Lipid Deposition, and Improves the Stability of Vulnerable Atherosclerotic Plaques by Modulating Autophagy. Front. Pharmacol. 2018, 9. https://doi.org/10.3389/fphar.2018.00438.
(45) Lennernäs, H. Clinical Pharmacokinetics of Atorvastatin. Clin. Pharmacokinet. 2003, 42 (13), 1141–1160. https://doi.org/10.2165/00003088-200342130-00005.
Downloads
Posted
License
Copyright (c) 2025 Eren Isbiliroglu, Reuben Dass
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.